September 6 - 9, 2019
Westin Copley Place
Abstract submission deadline: Sunday, June 23
Advance registration deadline: Friday, July 26
Friday, Sept. 6, 2019
Saturday, Sept. 7, 2019
Sunday, Sept. 8, 2019
Monday, Sept. 9, 2019
Friday, Sept. 6
and Keynote AddressesSession Chair: Brian M. Wolpin, Dana-Farber Cancer Institute, Boston, Massachusetts6-7:40 p.m.
Welcome from Cochairs
Rising Star KeynoteMechanisms and consequences of pancreatic cancer stromal evolutionMara H. Sherman, Oregon Health and Science University, Portland, Oregon
Opening KeynoteTargeting innate immunity in pancreatic carcinomaGeorge Miller, New York University Langone Health Perlmutter Cancer Center, New York, New York
Poster Session A / Opening Reception7:45-10 p.m.
Top of page
Saturday, Sept. 7
Continental Breakfast with Networking Roundtables7:30-8:30 a.m.
Plenary Session 1: Tumor MicroenvironmentSession Chair: Ben Z. Stanger, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania8:30-10:15 a.m.
Immune contexture of human pancreatic cancerLisa M. Coussens, Oregon Health and Science University, Portland, Oregon
Regulatory T cell depletion causes compensatory immune suppression and accelerates pancreatic carcinogenesisMarina Pasca Di Magliano, University of Michigan, Ann Arbor, Michigan
Heterocellular interactions in the tumor microenvironment Claus Jorgensen, Cancer Research UK Manchester Centre, Manchester, United Kingdom
Senescence induction triggers vascular remodeling and new vulnerabilities to chemo- and immunotherapy in pancreas cancer*
Marcus Ruscetti, Memorial Sloan Kettering Cancer Center, New York, New York
Plenary Session 2: GenomicsSession Chair: Andrew Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts10:45 a.m.-12:30 p.m.
Clonal evolution and progression of pancreatic cancer precursor lesionsLaura DeLong Wood, Johns Hopkins University, Baltimore, Maryland
Multimodal evolutionary dynamics of pancreatic cancerChristine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, New York
Molecular subtypes: Bench to bedsideJen Jen Yeh, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Loss of TET2 activity results in epigenetic instability and drives PDAC molecular subtypes* Eric O'Neill, University of Oxford, Oxford, United Kingdom
A novel deaminase independent function of APOBEC3A catalyzes widespread chromosomal instability to drive an aggressive metastatic phenotype in pancreatic cancer* Sonja Woermann, The University of Texas MD Anderson Cancer Center, Houston, Texas
Lunch (Provided)12:45-1:45 p.m.
Poster Session B 1:30-3:30 p.m.
Plenary Session 3: ImmunologySession Chair: Elizabeth M. Jaffee, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland3:30-5:30 p.m.
Link between adaptive and innate immunity in pancreatic cancerStephanie K. Dougan, Dana-Farber Cancer Institute, Boston, Massachusetts
Immune cell signaling in human and mouse pancreas cancerAida Habtezion, Stanford University, Stanford, California
Targeting pancreatic cancer with TCR-engineered T cellsPhil D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, Washington
STING and TLR independent activation of T cell responses against pancreatic cancer using agonistic CD40 antibody*
Katelyn Byrne, University of Pennsylvania, Philadelphia, Pennsylvania
Autophagy facilitates immune evasion of pancreatic cancer through downregulation of MHC class I molecules*
Keisuke Yamamoto, New York University School of Medicine, New York, New York
Evening Off / Dinner on Own5:30 p.m.
Sunday, Sept. 8
Continental Breakfast with Networking Roundtables7:30-8:30 a.m.
Plenary Session 4: Early-Stage Trials and Novel Treatment CombinationsSession Chair: Luis A. Diaz, Memorial Sloan Kettering Cancer Center, New York, New York8:30-10:30 a.m.
CD40 immunotherapy for pancreatic cancerRobert H. Vonderheide, University of Pennsylvania
Abramson Cancer Center, Philadelphia, Pennsylvania
Modulating the immune response with epigenetic agentsNilofer S. Azad, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Title to be announcedDiane M. Simeone, New York University, New York, New York
Multimodal mapping of the tumor microenvironment in pancreatic ductal adenocarcinoma*
Eileen Carpenter, University of Michigan, Ann Arbor, Michigan
Phase I/II study of mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma*Christine Alewine, National Cancer Institute, Bethesda, Maryland
Intratumoral T cell distribution in murine and patient pancreatic cancer correlates with tissue heterogeneity and survival*
Julienne Carstens, The University of Texas MD Anderson Cancer Center, Houston, Texas
Plenary Session 5: Ras and Oncogene SignalingSession Chair: Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York10:45 a.m.-12:30 p.m.
Deciphering the origins of PDAC developmentLaura D. Attardi, Stanford University School of Medicine, Stanford, California
KRAS and environmental signals regulate MYC to drive lineage plasticity, pancreas cancer progression, and therapeutic resistanceRosalie C. Sears, Oregon Health and Science University, Portland, Oregon
Wild-type KRAS in pancreatic cancer tumorigenesisGloria H. Su, Columbia University, New York, New York
KRas modulates pancreatic cancer cell metabolism and invasive potential through the lipase HSL*
Cody Rozeveld, Mayo Clinic, Rochester, Minnesota
Enhancing the effect of autophagy inhibition for pancreatic cancer treatment*
Kirsten Bryant, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Lunch (on Own)12:45-2 p.m.
Plenary Session 6: Prevention and Early DetectionSession Chair: Anirban Maitra, The University of Texas MD Anderson Cancer Center, Houston, Texas2-4 p.m.
Early detection of pancreatic cancer: Challenges and opportunitiesAnirban Maitra
Retooling a blood-based biomarker into a theranostic agentJason S. Lewis, Memorial Sloan Kettering Cancer Center, New York, New York
Circulating tumor DNA in cancer diagnosis: Challenges and potentialAnne Marie O'Broin-Lennon, Johns Hopkins Hospital, Baltimore, Maryland
Evaluation of the implementation of genetic cancer screening guidelines in African American pancreatic cancer patients in a safety net hospital* Taiwo Ajose, Morehouse School of Medicine, Atlanta, Georgia
The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice* Dannielle Engle, Salk Institute for Biological Studies, La Jolla, California
Poster Session C / Reception4-6:30 p.m.
Top of pageMonday, Sept. 9
Continental Breakfast7-8 a.m.
Plenary Session 7: MetabolismSession Chair: Alec C. Kimmelman, New York University Langone Medical Center, New York, New York8-9:45 a.m.
Title to be announcedMatthew G. Vander Heiden, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts
New players and unique features of cancer lysosomesRushika M. Perera, University of California San Francisco, San Francisco, California
Identifying metabolic dependencies in pancreatic cancerAlec C. Kimmelman
Targeting macrophage metabolism to improve therapy in pancreatic cancer*
Christopher Halbrook, University of Michigan, Ann Arbor, Michigan
Plenary Session 8: New Models, Systems, Animals, and BeyondSession Chair: Tyler Jacks, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts10-11:45 a.m.
Modeling pancreatic cancer in the mouseTyler Jacks
Title to be announcedScott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, New York
Investigating the immune microenvironment in mouse models of pancreatic cancerJen P. Morton, Cancer Research UK Beatson Institute, Glasgow, United Kingdom
Preclinical models to dissect immune escape in pancreatic cancer*
William Freed-Pastor, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts
Assessment of tumor heterogeneity, clonal evolution, and the stromal microenvironment in metastatic pancreatic ductal adenocarcinoma and matched patient-derived organoids*
Srivatsan Raghavan, Dana-Farber Cancer Institute, Boston, Massachusetts
Closing Keynote11:45 a.m.-12:30 p.m.
Pancreatic cancer immunotherapy: Moving forwardDung Thi Le, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Closing Remarks Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York12:30 p.m.
Top of page